The Breast Oncology Center at the Susan F. Smith Center for Women's Cancers at Dana-Farber provides state-of-the-art and compassionate care for breast cancer patients. Our breast cancer clinicians are committed to providing your patients with the best and most individualized treatment options available, including the latest medical oncology, surgical options, breast reconstruction, and radiation therapy.
Our focused and specialized services include programs for: young adults with breast cancer, metastatic breast cancer, inflammatory breast cancer, breast cancer during pregnancy, breast and ovarian cancer genetics and prevention, older adults with breast cancer, patients with breast cancer brain metastases, breast cancer in men, and ductal carcinoma in situ (DCIS).
View Treatment Guidelines and Other Resources Learn About Breast Cancer Breakthroughs Discover Progress in Gynecologic OncologyFeatured Content |view more
News
Cancer spreads, or metastasizes, when tumor cells shed from a primary solid tumor, for example in the breast, and embed in other organs, such as the lung, liver, and brain, and begin to grow.
News
The addition of a CDK 4/6 inhibitor to standard therapy in patients with “double-positive” metastatic breast cancer significantly extended the time the disease did not progress according to data published today in the New England Journal of Medicine.
News
ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer
In patients with advanced triple negative breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab led to durable responses and improved progression free survival compared to the current standard ...
Video
Ann Partridge, MD discusses YES study
Breast cancer survivors who used a novel mobile health intervention to self-manage post-treatment symptoms were able to improve their quality of life and reduce the burden of common symptoms, according to results of the YES study presented ...
Video
Stefania Morganti, MD discusses ctDNA study
Ultrasensitive detection of minimal residual disease using ctDNA can help predict the duration of response to HER2 targeted therapy in patients with metastatic breast cancer, according to a study presented by Stefani Morganti, MD, of Dana-Farber ...
Video
Paolo Tarantino, MD discusses the DATO - Base study
Paolo Tarantino, MD, of Dana-Farber Cancer Institute, presented new findings from the DATO-Base study examining treatment with the ADC Dato-DXd for women with leptomeningeal disease. Breast cancer is the most common cancer linked to this ...
